1) The document examines how the selective serotonin reuptake inhibitor (SSRI) citalopram impacts response inhibition in Parkinson's disease (PD). 2) It tests hypotheses that PD impairs the ability to restrain or cancel actions, and that citalopram's effects on behavior and brain activation depend on disease severity. 3) The results show that citalopram improved response inhibition in PD patients, and its impact correlated with increased activation in inferior frontal cortex and depended on disease severity.